Login

Switch On Your HIV Smarts.

Author Archives: Liz Highleyman

Can a Two-Drug Treatment Regimen Keep HIV Under Control?

Can a Two-Drug Treatment Regimen Keep HIV Under Control?

, by Liz Highleyman

HIV therapy with two drugs, instead of three, kept 90% of people undetectable in a small proof-of-concept study. Read More

AIDS 2016: Undetectable with long-acting, user-friendly injectable HIV medications

AIDS 2016: Undetectable with long-acting, user-friendly injectable HIV medications

, by Liz Highleyman

More than 90% of people receiving a long-acting injection of cabotegravir and rilpivirine maintained an undetectable HIV viral load. Read More

HIV Treatment Plus PrEP Virtually Eliminates HIV Transmission

HIV Treatment Plus PrEP Virtually Eliminates HIV Transmission

, by Liz Highleyman

HIV risk was reduced by 95% for people in serodiscordant relationships with PrEP and TasP, results of the Partners PrEP study show. Read More

AIDS 2016: San Francisco and New York Lead in PrEP Use

AIDS 2016: San Francisco and New York Lead in PrEP Use

, by Liz Highleyman

The manufacturer of Truvada reported how many prescriptions have been filled for PrEP—with a steep rise among men in 2015. Read More

FDA Approves Epclusa Combo Pill for All Types of Hepatitis C

FDA Approves Epclusa Combo Pill for All Types of Hepatitis C

, by Liz Highleyman

Epclusa is a new combo pill of sofosbuvir/velpatasvir that can cure hepatitis C in 12 weeks. Read More